375 related articles for article (PubMed ID: 22688083)
1. Patupilone (epothilone B) for recurrent glioblastoma: clinical outcome and translational analysis of a single-institution phase I/II trial.
Oehler C; Frei K; Rushing EJ; McSheehy PM; Weber D; Allegrini PR; Weniger D; Lütolf UM; Knuth A; Yonekawa Y; Barath K; Broggini-Tenzer A; Pruschy M; Hofer S
Oncology; 2012; 83(1):1-9. PubMed ID: 22688083
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial using patupilone (epothilone B) and concurrent radiotherapy for central nervous system malignancies.
Fogh S; Machtay M; Werner-Wasik M; Curran WJ; Bonanni R; Axelrod R; Andrews D; Dicker AP
Int J Radiat Oncol Biol Phys; 2010 Jul; 77(4):1009-16. PubMed ID: 19879067
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme.
Lassen U; Sorensen M; Gaziel TB; Hasselbalch B; Poulsen HS
Anticancer Res; 2013 Apr; 33(4):1657-60. PubMed ID: 23564811
[TBL] [Abstract][Full Text] [Related]
4. Multicenter phase 2 study of patupilone for recurrent or progressive brain metastases from non-small cell lung cancer.
Nayak L; DeAngelis LM; Robins HI; Govindan R; Gadgeel S; Kelly K; Rigas JR; Peereboom DM; Rosenfeld SS; Muzikansky A; Zheng M; Urban P; Abrey LE; Omuro A; Wen PY
Cancer; 2015 Dec; 121(23):4165-72. PubMed ID: 26308485
[TBL] [Abstract][Full Text] [Related]
5. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
[TBL] [Abstract][Full Text] [Related]
6. Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma. A phase II multicenter trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group.
Stupp R; Tosoni A; Bromberg JEC; Hau P; Campone M; Gijtenbeek J; Frenay M; Breimer L; Wiesinger H; Allgeier A; van den Bent MJ; Bogdahn U; van der Graaf W; Yun HJ; Gorlia T; Lacombe D; Brandes AA
Ann Oncol; 2011 Sep; 22(9):2144-2149. PubMed ID: 21321091
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution.
Combs SE; Thilmann C; Edler L; Debus J; Schulz-Ertner D
J Clin Oncol; 2005 Dec; 23(34):8863-9. PubMed ID: 16314646
[TBL] [Abstract][Full Text] [Related]
8. Stereotactic radiosurgery (SRS): treatment option for recurrent glioblastoma multiforme (GBM).
Combs SE; Widmer V; Thilmann C; Hof H; Debus J; Schulz-Ertner D
Cancer; 2005 Nov; 104(10):2168-73. PubMed ID: 16220556
[TBL] [Abstract][Full Text] [Related]
9. Treatment of recurrent glioblastoma multiforme with GliaSite brachytherapy.
Chan TA; Weingart JD; Parisi M; Hughes MA; Olivi A; Borzillary S; Alahakone D; Detorie NA; Wharam MD; Kleinberg L
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):1133-9. PubMed ID: 15990019
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort.
Metellus P; Coulibaly B; Nanni I; Fina F; Eudes N; Giorgi R; Barrie M; Chinot O; Fuentes S; Dufour H; Ouafik L; Figarella-Branger D
Cancer; 2009 Oct; 115(20):4783-94. PubMed ID: 19637364
[TBL] [Abstract][Full Text] [Related]
11. Phase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumors.
Rubin EH; Rothermel J; Tesfaye F; Chen T; Hubert M; Ho YY; Hsu CH; Oza AM
J Clin Oncol; 2005 Dec; 23(36):9120-9. PubMed ID: 16301595
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of epothilone B analog in advanced soft tissue sarcoma: a phase II study of the phase II consortium.
Okuno S; Maples WJ; Mahoney MR; Fitch T; Stewart J; Fracasso PM; Kraut M; Ettinger DS; Dawkins F; Erlichman C
J Clin Oncol; 2005 May; 23(13):3069-73. PubMed ID: 15860865
[TBL] [Abstract][Full Text] [Related]
13. Nimustine (ACNU) plus teniposide (VM26) in recurrent glioblastoma.
Glas M; Hundsberger T; Stuplich M; Wiewrodt D; Kurzwelly D; Nguyen-Huu B; Rasch K; Herrlinger U
Oncology; 2009; 76(3):184-9. PubMed ID: 19218824
[TBL] [Abstract][Full Text] [Related]
14. Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience.
D'Alessandris QG; Montano N; Cenci T; Martini M; Lauretti L; Bianchi F; Larocca LM; Maira G; Fernandez E; Pallini R
Acta Neurochir (Wien); 2013 Jan; 155(1):33-40. PubMed ID: 23132371
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma.
Lee EQ; Reardon DA; Schiff D; Drappatz J; Muzikansky A; Grimm SA; Norden AD; Nayak L; Beroukhim R; Rinne ML; Chi AS; Batchelor TT; Hempfling K; McCluskey C; Smith KH; Gaffey SC; Wrigley B; Ligon KL; Raizer JJ; Wen PY
Neuro Oncol; 2015 Jun; 17(6):862-7. PubMed ID: 25572329
[TBL] [Abstract][Full Text] [Related]
16. A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy.
Møller S; Grunnet K; Hansen S; Schultz H; Holmberg M; Sorensen M; Poulsen HS; Lassen U
Acta Oncol; 2012 Jul; 51(6):797-804. PubMed ID: 22548369
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of gefitinib in recurrent glioblastoma.
Rich JN; Reardon DA; Peery T; Dowell JM; Quinn JA; Penne KL; Wikstrand CJ; Van Duyn LB; Dancey JE; McLendon RE; Kao JC; Stenzel TT; Ahmed Rasheed BK; Tourt-Uhlig SE; Herndon JE; Vredenburgh JJ; Sampson JH; Friedman AH; Bigner DD; Friedman HS
J Clin Oncol; 2004 Jan; 22(1):133-42. PubMed ID: 14638850
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of ifosfamide, carboplatin, and etoposide in patients with a first recurrence of glioblastoma multiforme.
Aoki T; Mizutani T; Nojima K; Takagi T; Okumura R; Yuba Y; Ueba T; Takahashi JA; Miyatake S; Nozaki K; Taki W; Matsutani M
J Neurosurg; 2010 Jan; 112(1):50-6. PubMed ID: 19538050
[TBL] [Abstract][Full Text] [Related]
19. Single-agent bevacizumab is an effective treatment in recurrent glioblastoma.
Hacibekiroglu I; Kodaz H; Erdogan B; Turkmen E; Ozcelik M; Esenkaya A; Saygi HM; Uzunoglu S; Cicin I
Med Oncol; 2015 Feb; 32(2):460. PubMed ID: 25572814
[TBL] [Abstract][Full Text] [Related]
20. A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas.
Raizer JJ; Grimm S; Chamberlain MC; Nicholas MK; Chandler JP; Muro K; Dubner S; Rademaker AW; Renfrow J; Bredel M
Cancer; 2010 Nov; 116(22):5297-305. PubMed ID: 20665891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
